Market Overview:
The global androgenic alopecia drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of androgenic alopecia, rising awareness about available treatment options, and growing demand for hair restoration products. Based on type, the global androgenic alopecia drug market is segmented into RK-023, Refagro, RCH-01, SM-04554, HYG-440, and others. The RK-023 segment is expected to account for the largest share of the global market in 2018 owing to its high efficacy and safety profile. Based on application, the global market is segmented into clinic use, hospital use (including ambulatory surgical centers), and home use.
Product Definition:
Androgenic Alopecia Drug is a drug used to treat androgenetic alopecia, a type of hair loss caused by an over-activity of the male sex hormones (androgens).
RK-023:
RK-023 is a novel androgenic alopecia growth factor that works by promoting hair growth in the scalp. It has been found to be effective in treating women with Androgenic Alopecia who have not experienced any positive response from Finasteride or Dutasteride.
Refagro:
Refagro (Remiclorac) is used for the treatment of androgenic alopecia. It works by reducing hair loss in men and women. According to the National Institutes of Health, more than 50 million Americans suffer from some form of alopecia areata. This condition is more common in people aged between 20-60 years but can occur at any age.
Application Insights:
The global androgenic alopecia drug market has been segmented on the basis of application into clinic, hospital, and home use. The home use segment held a major share in 2017 owing to increasing awareness about hair loss among men and women across the globe. Moreover, easy availability of online products is also expected to drive demand for these drugs at home settings.
The hospital application segment is expected to witness lucrative growth over the forecast period due to rising prevalence of male pattern baldness (MPB) among patients admitted in hospitals for treatment or surgery involving scalps.
Regional Analysis:
North America dominated the global androgenic alopecia drug market in 2016. The presence of key players, favorable reimbursement scenario, and high adoption rate of Androgenetic Alopecia (AGA) drugs are some factors responsible for its large share. In addition, increasing prevalence of target diseases such as prostate cancer is expected to drive the demand for anti-androgens in this region. For instance, according to a study conducted by National Cancer Institute (NCI), prostate cancer is one of the most common cancers among men in North America accounting for nearly 1 million new cases every year with an average life expectancy of nearly seven years from diagnosis.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income leading towards increased healthcare expenditure along with growing awareness about early diagnosis & treatment options available for AGA patients coupled with rapidly improving healthcare infrastructure & services especially in developing countries such as India.
Growth Factors:
- Increasing prevalence of androgenic alopecia
- Growing awareness about the available treatment options for androgenic alopecia
- Rising demand for hair restoration procedures
- Technological advancements in the field of hair restoration therapies
- increasing number of male patients suffering from androgenic alopecia
Scope Of The Report
Report Attributes
Report Details
Report Title
Androgenic Alopecia Drug Market Research Report
By Type
RK-023, Refagro, RCH-01, SM-04554, HYG-440, Others
By Application
Clinic, Hospital, Home Use
By Companies
Allergan, Inc., Histogen, Inc., R-Tech Ueno, Ltd., Hygeia Therapeutics, Inc., SWITCH Biotech LLC, Polichem S.A., Kasiak Research Pvt. Ltd., Allergan, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Androgenic Alopecia Drug Market Report Segments:
The global Androgenic Alopecia Drug market is segmented on the basis of:
Types
RK-023, Refagro, RCH-01, SM-04554, HYG-440, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Home Use
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan, Inc.
- Histogen, Inc.
- R-Tech Ueno, Ltd.
- Hygeia Therapeutics, Inc.
- SWITCH Biotech LLC
- Polichem S.A.
- Kasiak Research Pvt. Ltd.
- Allergan, Inc.
Highlights of The Androgenic Alopecia Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- RK-023
- Refagro
- RCH-01
- SM-04554
- HYG-440
- Others
- By Application:
- Clinic
- Hospital
- Home Use
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Androgenic Alopecia Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Androgenic alopecia is a type of hair loss that is caused by hormones. Hormones can be produced by the body in response to stress, illness, or other factors. Androgenic alopecia can occur on any part of the body, but it most commonly affects the scalp.
Some of the major companies in the androgenic alopecia drug market are Allergan, Inc., Histogen, Inc., R-Tech Ueno, Ltd., Hygeia Therapeutics, Inc., SWITCH Biotech LLC, Polichem S.A., Kasiak Research Pvt. Ltd., Allergan, Inc..
The androgenic alopecia drug market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Androgenic Alopecia Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Androgenic Alopecia Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Androgenic Alopecia Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Androgenic Alopecia Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Androgenic Alopecia Drug Market Size & Forecast, 2020-2028
4.5.1 Androgenic Alopecia Drug Market Size and Y-o-Y Growth
4.5.2 Androgenic Alopecia Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 RK-023
5.2.2 Refagro
5.2.3 RCH-01
5.2.4 SM-04554
5.2.5 HYG-440
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Home Use
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Androgenic Alopecia Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Androgenic Alopecia Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 RK-023
9.6.2 Refagro
9.6.3 RCH-01
9.6.4 SM-04554
9.6.5 HYG-440
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Home Use
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 RK-023
10.6.2 Refagro
10.6.3 RCH-01
10.6.4 SM-04554
10.6.5 HYG-440
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Home Use
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 RK-023
11.6.2 Refagro
11.6.3 RCH-01
11.6.4 SM-04554
11.6.5 HYG-440
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Home Use
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 RK-023
12.6.2 Refagro
12.6.3 RCH-01
12.6.4 SM-04554
12.6.5 HYG-440
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Home Use
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 RK-023
13.6.2 Refagro
13.6.3 RCH-01
13.6.4 SM-04554
13.6.5 HYG-440
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Home Use
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Androgenic Alopecia Drug Market: Competitive Dashboard
14.2 Global Androgenic Alopecia Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan, Inc.
14.3.2 Histogen, Inc.
14.3.3 R-Tech Ueno, Ltd.
14.3.4 Hygeia Therapeutics, Inc.
14.3.5 SWITCH Biotech LLC
14.3.6 Polichem S.A.
14.3.7 Kasiak Research Pvt. Ltd.
14.3.8 Allergan, Inc.
